Lymphoma

Long-term follow-up of the JULIET trial showed patients with relapsed or refractory DLBCL continued to experience durable responses 19 months after treatment.

Especially during holiday seasons, we remember loved ones who are not with us. Even long after they have passed, we can cherish old memories and even make new ones with the help of social media. Recently I learned something sweet about my brother John, who died of Hodgkin's lymphoma decades ago, from a high school friend I never knew about.

Treatment with Xarelto (rivaroxaban) may reduce the risk for developing blood clots during active treatment with a systemic therapy like chemotherapy, according to results from the CASSINI trial.

The Food and Drug Administration (FDA) approved Truxima (rituximab-abbs) – the first biosimilar of Rituxan (rituximab) – to treat adults with CD20-positive, B-cell non-Hodgkin lymphoma (NHL).

Jeff Young, D.V.M., refused to let cancer stop him from living.

The Food and Drug Administration (FDA) expedited the approval of Adcetris (brentuximab vedotin) in combination with chemotherapy for certain patients with peripheral T-cell lymphoma (PTCL).

The Food and Drug Administration (FDA) granted a breakthrough therapy designation to Adcetris (brentuximab vedotin) for the frontline treatment of certain lymphoma subtypes, according to Seattle Genetics, the manufacturer of the antibody-drug conjugate.

Preventing febrile neutropenia is crucial because the body’s white blood cells help to fight infection.

Lawrence D. Kaplan, M.D., discusses recent updates and next steps to be taken in Hodgkin, mantle cell and follicular lymphoma.

Entospletinib monotherapy yielded limited activity in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma.

The Food and Drug Administration (FDA) granted fast track designation to selinexor for the treatment of patients with diffuse large B-cell lymphoma (DLBCL), according to Karyopharm Therapeutics, the drug’s manufacturer.

People with slow-growing B-cell lymphomas and no symptoms are often prescribed a watch-and-wait approach, which involves monitoring until the disease grows and warrants treatment.

Treating older patients who have Hodgkin lymphoma with Adcetris (brentuximab vedotin) before and after chemotherapy showed improved remission and survival rates, according to phase 2 study findings.

The Food and Drug Administration has granted a priority review to the supplemental new drug application for Jakafi (ruxolitinib) to treat patients with acute graft-versus-host-disease (GVHD) who have had an inadequate response to corticosteroids.

When Paul Isenberg’s wife, Nicole, was diagnosed with stage 4 Hodgkin lymphoma shortly after the birth of their child, Gabrielle, the couple realized two things: how blessed they were and that some people going through cancer have nobody to turn to.

I'm using the lessons that cancer taught me to move forward in life.

The Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee voted 16-0 in support of the agency granting approval to CT-P10, a biosimilar of Rituxan (rituximab), which is a drug used to treat non-Hodgkin lymphoma.

I shared some advice with another soon-to-be caregiver.

The drug was approved for adults with chronic lymphocytic leukemia and small lymphocytic lymphoma. And was granted an accelerated approval for follicular lymphoma.

September is Blood Cancer Awareness month and CURE’s latest issue is dedicated to these diseases. And we have a sneak peek at what’s inside:

From an inaugural gathering in 2009 that attracted approximately 700 people, the Life and Liberty event has grown in size each year, with more than 4,000 patients in attendance at last September’s celebration. Organizers said about 6,000 were there this year.

The Cutaneous Lymphoma Foundation connects patients with guidance and resources for this rare cancer.

Nicholas J. Vogelzang, M.D., FASCO, FACP, has seen cancer through a variety of lenses – from oncologist to patient as well as caregiver – giving him a different perspective than most.

Injectable forms of medication may benefit patients with blood cancers.

Team physician James Muntz diagnosed the blood cancer, and Hal then consulted with oncologists at The University of Texas MD Anderson Cancer Center in Houston.